FDA Approves Third Alzheimer’s Drug, Just as Diagnostic Criteria Expand

The new definition of Alzheimer’s as any abnormal level of amyloid beta or tau — even in the absence of symptoms — could vastly expand the market for treating the disease, just as the FDA approved its third antiamyloid antibody, Lilly’s Kisunla (donanemab).
Source: Drug Industry Daily